MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details) - USD ($)					1 Months Ended		2 Months Ended	3 Months Ended			6 Months Ended
	May 25, 2023	Apr. 27, 2023	Aug. 03, 2022	Aug. 01, 2022	May 31, 2022	Jan. 31, 2022	Feb. 28, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized				70,000,000				70,000,000			70,000,000		70,000,000
Preferred stock, shares authorized				30,000,000				30,000,000			30,000,000		30,000,000
Common stock, par value								$ 0.0001			$ 0.0001		$ 0.0001
Common stock, shares issued								13,648,425			13,648,425		10,955,904
Issuance of common shares in connection with follow-on offering, net of issuance costs								$ 4,156,859
Common stock per share							$ 9.00
Gross proceeds from sale of common stock			$ 9,093,830		$ 99,999		$ 2,373,561					$ 2,473,560
Warrants exercise price, per share				$ 6.25
Transaction costs					$ 0		$ 0
Deemed dividend on warrant modification												$ (450,578)
Warrants exercised, shares					394,501
Cashless exercise at fair market value per share					$ 9
Issuance of common shares upon cashless exercise of warrants, shares					315,601
Stock options outstanding								7,781,325			7,781,325		6,545,628
Fair value assumptions, contractual term											7 years
Exercise price percentage											110.00%
Percentage of shares granted											10.00%
Warrants and rights exercisable period				Jan. 23, 2023
Class of warrant or right date from which warrants or rights expire				Jul. 27, 2027
Warrants								$ 121,600			$ 121,600		$ 245,341
Gain on remeasurement of warrant liability								$ (102,799)			(123,741)
Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate			2.82%
Volatility rate			77.50%
Fair value assumptions, contractual term			5 years
Warrants			$ 343,735
Gain on remeasurement of warrant liability											$ 123,741
January 1 to January 26, 2022
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value									$ 8.87			$ 8.87
January 27 to May 31, 2022
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share								$ 9			$ 9
June 1 to June 30, 2022
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share								$ 5			$ 5
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term											10 years
Warrants to purchase aggregate of common stock				100,000
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance								0			0
Stock options outstanding								1,924,500			1,924,500
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance								0			0
Stock options outstanding								3,957,710			3,957,710
2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance				1,909,518				1,992,709			1,992,709			1,956,993
Stock options outstanding								1,899,115			1,899,115
Percentage of increase in stock outstanding fully diluted	10.00%
IPO
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued				219,872
Number of common stock sold				2,000,000
Issuance of common shares in connection with follow-on offering, net of issuance costs				$ 1,099,360
Common stock per share				$ 5.00			$ 5.00
Gross proceeds from common stock				$ 10,000,000
Number of warrants exercise				20,520
Warrants exercise price, per share				$ 5.00
Overallotment Option
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold			300,000
Common stock per share			$ 5.00
Gross proceeds from common stock			$ 1,500,000
Overallotment Option \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right additional purchase aggregate of common stock			15,000
Follow-on Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share				$ 2.81
Risk free interest rate				4.09%
Volatility rate				86.30%
Fair value assumptions, contractual term				5 years
Warrants and rights exercisable period				Oct. 24, 2023
Class of warrant or right date from which warrants or rights expire				Apr. 24, 2028
Class of warrant or right additional purchase aggregate of common stock				241,009
Follow-on Offering \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock				127,775
Common Stock
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold					11,111		263,729	2,555,500
Sale of common stock, price per share					$ 9		$ 9.00
Issuance of common shares in connection with follow-on offering, net of issuance costs								$ 256
Issuance of common shares upon exercise of warrants, Shares					153,000	61,111			468,601	61,111
Proceeds from issuance of common stock upon exercise of warrants					$ 275,400	$ 110,000
Founder
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense												$ 52,500
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense											$ 488,600
Shares granted											137,021
Unvested shares								0			0
Restricted Stock Awards \| Founder
Subsidiary or Equity Method Investee [Line Items]
Shares granted												29,168
MAIA Stock Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrant modification, value						$ 144,497
Deemed dividend on warrant modification												$ 450,578
Stock Options
Subsidiary or Equity Method Investee [Line Items]
Weighted-average grant date fair value											$ 3.26	$ 5.97
Unrecognized compensation								$ 4,494,698			$ 4,494,698
Unrecognized compensation expense, recognized period											3 years 1 month 6 days
Stock Options \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term											6 years 3 months	6 years 3 months
Stock Options \| Minimum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term											5 years	5 years
ThinkEquity LLC \| Follow-on Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold		2,555,500
Common stock per share		$ 2.25
Gross proceeds from common stock		$ 4,398,000